A detailed history of Nisa Investment Advisors, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 176 shares of VIR stock, worth $1,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares
176
Previous 167 5.39%
Holding current value
$1,318
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$7.63 - $12.66 $68 - $113
9 Added 5.39%
176 $1,000
Q1 2024

May 01, 2024

BUY
$8.6 - $11.9 $946 - $1,309
110 Added 192.98%
167 $1,000
Q4 2023

Jan 25, 2024

BUY
$7.76 - $10.29 $209 - $277
27 Added 90.0%
57 $0
Q3 2023

Nov 02, 2023

SELL
$9.14 - $24.62 $12,722 - $34,271
-1,392 Reduced 97.89%
30 $0
Q2 2023

Aug 11, 2023

BUY
$23.2 - $27.29 $8,630 - $10,151
372 Added 35.43%
1,422 $34,000
Q3 2022

Nov 07, 2022

BUY
$18.26 - $31.1 $913 - $1,555
50 Added 5.0%
1,050 $23,000
Q2 2022

Aug 03, 2022

BUY
$19.08 - $26.7 $10,684 - $14,952
560 Added 127.27%
1,000 $25,000
Q1 2022

Apr 29, 2022

SELL
$21.19 - $40.01 $20,978 - $39,609
-990 Reduced 69.23%
440 $11,000
Q4 2021

Feb 03, 2022

BUY
$30.97 - $54.03 $28,802 - $50,247
930 Added 186.0%
1,430 $49,000
Q1 2021

Apr 26, 2021

SELL
$26.34 - $83.07 $17,384 - $54,826
-660 Reduced 56.9%
500 $26,000
Q4 2020

Jan 25, 2021

SELL
$25.51 - $43.38 $35,790 - $60,862
-1,403 Reduced 54.74%
1,160 $31,000
Q3 2020

Oct 20, 2020

BUY
$28.28 - $53.6 $59,472 - $112,720
2,103 Added 457.17%
2,563 $88,000
Q2 2020

Jul 27, 2020

BUY
$27.89 - $47.86 $10,040 - $17,229
360 Added 360.0%
460 $19,000
Q1 2020

Apr 17, 2020

BUY
$12.04 - $60.2 $1,204 - $6,020
100 New
100 $3,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $993M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.